Abstract
Efficacy of ertapenem in biliary tract infections in daily practice was retrospectively analyzed. Records of patients admitted to five Spanish hospitals (January 2007/February 2011) with biliary infections (cholecystitis/cholangitis) treated with ertapenem for ⩾72 hours were reviewed. A total of 187 patients (mean 63·8±19·3 years, 52·9% males) were identified. Up to 96 (51·3%) were operated, with cholecystectomy (97·9%) and primary laparoscopy approach (75%) as most frequent intervention. Non-operated patients presented higher age (71·0±17·5 vs 56·9±18·5 years; P<0·001), heart insufficiency (11·0 vs 3·1%; P = 0·044) and the Mortality in Emergency Department Sepsis score (2·99±2·26 vs 1·94±2·34; P<0·001); and longer length of stay (10·3±6·6 vs 9·1±7·0; P = 0·005). Mean duration of treatment was 6·89±3·38 days. Overall favourable response was 87·7% (95% CI = 83·0–92·4) at the end of treatment. In the multivariate analysis (P<0·001, R2 Cox = 0·10), non-favourable response was associated with Charlson index⩾5 (OR = 18·71; 95% CI: 1·26–278·55; P = 0·034), pericholecystic abscess (OR = 5·30; 95% CI: 1·26–22·37; P = 0·023) and >3 days from symptoms start to admission (OR = 3·02; 95% CI: 1·13–8·04; P = 0·027).
We thank P. Yuste and R. Cavanillas for their continuous support during this study.